Guardant Health has surged 22% in a week and 35% in a month — and the company's own executives are using the run-up to sell.
The insider activity is the standout this week. On May 20, founder and CEO Amirali Talasaz sold across multiple tranches, offloading roughly 115,000 shares worth approximately $13.6 million at prices ranging from $105 to $112. The Chief Commercial Officer added another $2.9 million sale on May 22. The Chief Legal Officer and two independent directors also sold on May 20. Over the trailing 90 days, net insider activity is a positive $34.5 million in value terms — but that figure reflects the scale of the activity, not the direction. Every recent trade in the data is a sale. Selling into strength after a sharp rally is common and often reflects pre-scheduled plans, but the breadth of participation — CEO, CCO, CLO, and two directors all on the same day — is the kind of cluster worth noting ahead of the June 17 earnings call.
The borrow market tells a relaxed story. Availability is running at 1,144% of outstanding short interest — ample room in the lending pool, and well above the 52-week trough of 682% reached on May 5. Cost to borrow has crept up roughly 62% on the week to 0.49%, but that remains objectively low. Short interest itself is essentially flat on the week at 9.4% of the free float, virtually unchanged from where the last note left it. Shorts have not meaningfully added into the rally, nor have they rushed to cover. The orderly short retreat documented earlier this month has stalled, with shares short holding steady near 12.2 million. Options positioning has shifted modestly more defensive — the put/call ratio is 0.79, a touch above its 20-day average of 0.72, but the z-score of 0.54 puts that nowhere near an alarm level. The overall lending and options picture is calm relative to the stock's recent price action.
Analysts are chasing the stock higher. BTIG raised its target to $155 on May 26, then lifted again to $160 on May 27 — two upward revisions in two days. JP Morgan bumped its Overweight target to $135 on May 8 following the prior earnings print. Barclays raised to $120 on the same day. The consensus is a firm buy with 15 buy-rated analysts and a mean target that — even after the recent upgrades — lags the current price on some desks. Evercore's In-Line rating with a $95 target is an outlier, sitting well below the current $119.85 close, and represents the main dissenting voice. The bull case rests on Guardant's dominant share in circulating genomic profiling liquid biopsy — over 50% of that segment — and near-30% year-on-year volume growth. Bears focus on PAMA reimbursement regulations, which could trigger an estimated $100 million one-time revenue reduction, and ongoing average selling price pressure. The EPS surprise factor score of 89 out of 100 suggests the company has consistently beaten estimates, but the 12-month forward EPS trajectory (ranked in the 99th percentile for year-on-year improvement) is doing heavy lifting to justify a stock trading at deeply negative trailing multiples.
Among peers, OPK rose 14% on the week and AIRS gained 15%, broadly tracking GH's move. NEO was up 11% and FLGT added 11%. The rally is not unique to Guardant — diagnostics and health services names have had a strong week — but GH's 22% move is at the top of the peer range, suggesting some stock-specific momentum beyond the sector tailwind.
The June 17 Q1 earnings call is the next focal point. The most recent print on May 7 produced a 3.7% next-day gain and a 6.9% five-day gain. The print before that — on April 30 — delivered a 5% next-day move and a 10.6% five-day gain. Both prior reactions were positive. The setup heading in is a stock at multi-month highs, insiders selling at current prices, analysts with fresh upward revisions, and a borrow market with no meaningful squeeze pressure either way — the key question is whether the reimbursement narrative around PAMA and MCED test coverage has materially shifted.
See the live data behind this article on ORTEX.
Open GH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
